ArticleNucleic acids research2026
DNA secondary structures in BCL2 and MYC elicit activation-induced cytidine deaminase binding and activity.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Activation-induced cytidine deaminase (AID) diversifies the immunoglobulin repertoire by targeting cytosines in specific hotspots. While AID is tightly regulated and largely confined to immunoglobulin loci, its activity at nonimmunoglobulin sites is linked to oncogenic mutagenesis. Mechanisms underlying AID targeting are not completely understood, though recent evidence indicates G4 structures are preferred AID substrates. Here, we use well-characterized structure-forming sequences from the BCL2 and MYC promoters, proposed AID off-targets in lymphoma, to investigate AID recognition of oncogene-associated secondary structures. Our work shows AID binds and deaminates G4s from both oncogenes. AID deaminates two specific cytosines in the BCL2 G4, each three nucleotides from a G-tetrad confirming previous position-dependent AID activity. Oligo-seq reveals distinct sequence contexts required for efficient deamination of these cytosines. In assessing the complementary DNA to the G4, we identify the i-Motif as a novel determinant of AID interaction. Using AID paralogs A3C, A3A, and A2, our findings highlight that DNA secondary structures differentially influence APOBEC deaminase binding and activity. Furthermore, mutation of AID residue glutamine 135 to its A3C cognate alanine disrupts both binding and deamination. This study establishes AID interacts with nonimmunoglobulin DNA structures implicating these promoter elements in AID recruitment to off-target sites in oncogenes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.